Roivant Sciences Ltd.ROIV
NasdaqGS•Healthcare•Biotechnology
Analyze revenue and earnings growth — the core drivers of long-term shareholder returns.
TTM revenue reached $8.26M, declining 71.6% year-over-year. TTM net income stood at $-299.77M (74.3% contraction). Quarterly EBITDA was $417.49M and operating income was $415.24M. Consistent revenue and earnings growth are the primary drivers of long-term shareholder returns. Analyze ROIV growth trends across revenue, EBITDA, operating income, and net income.
Revenue and earnings growth across quarters